Survivors and Caregivers FAQ

Your IpsiHand may be covered by insurance.

Neurolutions assists stroke survivors with obtaining insurance coverage and reimbursement for IpsiHand.

In order to provide these services on your behalf, Neurolutions must obtain and share certain information about you from your doctor, other health care providers, and each of your health insurers.

No, we can work with your clinician if you are currently enrolled in a rehabilitation therapy program. In addition, our Clinical Team consists of experienced Occupational Therapists with advanced certifications to provide you with assistance and information for screening and set-up of the IpsiHand System.

One hundred percent of clinical trial participants saw an improvement in their arm and/or hand function following participation in the study. Our clinical trials demonstrated clinically significant arm and hand improvement for 66.7% of trial participants. The IpsiHand study protocols required the use of the device approximately 1 hour per day, 5 to 7 days a week for a total of at least 12 weeks in patients 6 or more months post-stroke. Participants in our clinical trials used the IpsiHand system at home for the duration of the study.

The IpsiHand will be available for potential candidates at select locations throughout the US this year. Make sure you are on our mailing list to receive updates about our location for trialing the device.

No, we can work with your clinician if you are currently enrolled in a rehabilitation therapy program. In addition, our Clinical Team consists of experienced Occupational Therapists with advanced certifications to provide you with assistance and information for screening and set-up of the IpsiHand System.

One hundred percent of clinical trial participants saw an improvement in their arm and/or hand function following participation in the study. Our clinical trials demonstrated clinically significant arm and hand improvement for 66.7% of trial participants. The IpsiHand study protocols required the use of the device approximately 1 hour per day, 5 to 7 days a week for a total of at least 12 weeks in patients 6 or more months post-stroke. Participants in our clinical trials used the IpsiHand system at home for the duration of the study.

FDA De Novo approval establishes a new medical device type and approves that the device is safe to be used. De Novo classified devices did not fit into an established category and there were no equivalent devices on the market at the time of approval.